Hepion Pharmaceuticals | 10-Q: FY2025 Q3 Revenue: USD 0

Revenue: As of FY2025 Q3, the actual value is USD 0.

EPS: As of FY2025 Q3, the actual value is USD -0.04.

EBIT: As of FY2025 Q3, the actual value is USD -536.02 K.

Operational Metrics

• Net Loss: For the three months ended September 30, 2025, the net loss was $472,506, compared to $4,865,948 for the same period in 2024, showing a significant reduction in losses.
• Total Operating Expenses: Total operating expenses for the three months ended September 30, 2025, were $527,902, a decrease from $4,458,259 in the same period in 2024.

Cash Flow

• Net Cash Used in Operating Activities: For the nine months ended September 30, 2025, net cash used in operating activities was $2,938,745, compared to $17,063,429 for the same period in 2024.
• Net Cash Provided by Financing Activities: For the nine months ended September 30, 2025, net cash provided by financing activities was $4,985,532, compared to $4,349,707 for the same period in 2024.

Future Outlook and Strategy

• Core Business Focus: The company plans to increase research and development expenses as it pursues the development of assets acquired from New Day Diagnostics LLC, which include diagnostic tests eligible for sale in the EU and certain markets that accept the CE mark.
• Non-Core Business: The company has divested its Rencofilstat assets to Panetta Partners Limited, with contingent value rights for future milestone payments, indicating a shift away from its previous focus on drug therapy for chronic liver diseases.

Unique Metrics

• License Agreement with New Day Diagnostics LLC: The company entered into a license agreement to in-license diagnostic tests for celiac disease, respiratory multiplex, H. pylori, and HCC, with potential milestone payments up to $17.15 million and royalties based on net sales.